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The Effect on Colon Visualization During Colonoscopy
of the Addition of Simethicone to Polyethylene
Glycol-Electrolyte Solution: A Randomized
Single-Blind Study
Rebecca Matro, MD1, Keegan Tupchong, MD2, Constantine Daskalakis, ScD3, Victoria Gordon4, Leo Katz, MD1 and
David Kastenberg, MD1

OBJECTIVES: Colonic bubbles associated with polyethylene glycol-electrolyte solution (PEG-ELS) are common and obscure
mucosal visualization. This study aimed to determine whether adding simethicone decreases the incidence of bubbles.
METHODS: Prospective, single-blind, randomized comparison of split dose PEG-ELS vs. PEG-ELS þ simethicone (PEG-S) for
outpatient colonoscopy. Bubble severity for colonic segments was assessed on withdrawal as A ¼ no/minimal bubbles,
B ¼ moderate bubbles/interfere with detecting 5 mm polyp, C ¼ severe bubbles/interfere with detecting 10 mm polyp. Primary
end point was Grade B or C bubbles in any colon segment. Secondary end points were cleansing quality, incidence and severity
of side effects, and polyp detection.
RESULTS: One hundred and thirty nine patients enrolled; 13 withdrew before colonoscopy. Of 123 patients evaluated, 62 took
PEG-S and 61 PEG-ELS. The incidence of grade B or C bubbles was much lower with PEG-S compared with PEG-ELS (2% vs.
38%; P ¼ 0.001). Overall cleansing (excellent or good) quality was not significantly different for either the whole colon (89% PEGELS, 94% of PEG-S, P ¼ 0.529) or right colon (88% PEG-ELS, 94% PEG-S, P ¼ 0.365). More PEG-S patients had excellent rather
than good preps (whole colon 53% vs. 28%, P ¼ 0.004; right colon 53% vs. 35%, P ¼ 0.044). Need for any flushing was less with
PEG-S (38% vs. 70%, P ¼ 0.001). The groups were not significantly different with respect to total procedure and withdrawal times,
incidence or severity of side effects, or number of polyps/patient or adenomas/patient.
CONCLUSIONS: Adding simethicone to PEG-ELS effectively eliminates bubbles, substantially reduces the need for flushing, and
results in more excellent preparations.
Clinical and Translational Gastroenterology (2012) 3, e26; doi:10.1038/ctg.2012.16; published online 29 November 2012
Subject Category: Endoscopy

INTRODUCTION
Effective bowel purgation is requisite for performance of high
quality colonoscopy.1–3 Bowel preparation may be inadequate
in up to 25% of patients undergoing colonoscopy and may
result in missed lesions during colorectal cancer screening.4–6
Subsequently, reporting the adequacy of colon cleansing
using one of the several available scales is an important
measure of colonoscopy quality.7–9 Such scales consider the
presence, character, and quantity of residue as well as the
ease with which it may be removed by means of flushing and
suctioning. Besides liquid and solid debris, adherent chyme
may be an important limitation in the evaluation of the proximal
colon—particularly in patients with a long interval between the
last dose of purgative and the colonoscopy.10
Another variable affecting mucosal visualization is colonic
bubbles. Although presence and severity of bubbles are not
typically commented on when describing preparation quality,
the widespread practice of adding simethicone to water
flushes during the performance of colonoscopy suggests that
impaired mucosal visibility from bubbles is commonplace. In
1

fact, up to one-third of patients receiving polyethylene glycolelectrolyte solution (PEG-ELS) have bubbles at the time of
colonoscopy that may potentially interfere with polyp detection.1,11–14 Simethicone, which eliminates bubbles by
decreasing surface tension, is a well-tolerated over-thecounter medication used for gas and bloating.1,13
The purpose of this study was to evaluate whether the
addition of simethicone to PEG-ELS, administered as a split
dose the evening before and morning of colonoscopy,
reduces the incidence of colonic bubbles that could interfere
with polyp detection.

METHODS
This was a prospective, randomized, investigator-blinded
study comparing 2 l PEG-ELS to PEG-ELS with simethicone
(PEG-S), both administered as a split dose, in patients
undergoing elective outpatient colonoscopy. All patients
provided written informed consent. The study was conducted
at a single university, and was approved by the university’s
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Institutional Review Board. The study was registered nationally with clinicaltrials.gov, number NCT01209806.
Subjects. Patients 18 years of age or older scheduled to
undergo elective outpatient colonoscopy were eligible to
participate. Exclusion criteria included pregnancy, breast
feeding, known or suspected gastroparesis, known or
suspected bowel obstruction, severe constipation (r1 bowel
movement per week), 450% colon resection, glucose-6phosphate dehydrogenase deficiency, PEG allergy, significant
psychiatric illness, or inability to provide informed consent.
Study design: randomization and protocol. Using a
randomization schedule generated by the website Randomization.com,
(http://www.randomization.com),
eligible
patients were randomly assigned to PEG-ELS or PEG-S by
an investigator not involved in the colonoscopy procedure.
Commercially available 2 l PEG-ELS containing sodium
sulfate, sodium ascorbate, and ascorbic acid (MoviPrep,
Salix Pharmaceuticals, Morrisville, NC) and liquid simethicone (Qualitest Pharmaceuticals, Huntsville, AL) were used.
Subjects were provided with a standard PEG-ELS kit and
given detailed instructions regarding preparation of the PEGELS, the addition of simethicone if randomized to that
treatment arm, and routine instructions for colonoscopy
including diet, hydration, and when to begin fasting. The
patient’s endoscopist was not involved in the randomization
process and remained blinded for the duration of the study.
Subjects randomized to PEG-ELS took 1 l of PEG-ELS plus
500 cc of clear liquids at 6 PM the night before colonoscopy,
and this was repeated 4 h before colonoscopy PM/AM dosing.
Subjects randomized to PEG-S also consumed 1 l of PEG-ELS
plus 500 cc of clear liquids at 18:00 hours the night prior and 4 h
before the colonoscopy. However, 400 mg of simethicone was
added to each liter of PEG-ELS as follows. PEG-ELS was
mixed as instructed by the manufacturer and refrigerated
before each 1 l was taken. Immediately before consuming the
purgative, simethicone was added to chilled PEG-ELS by filling
a 0.6 ml dropper with liquid simethicone (40 mg simethicone/
0.6 ml) 10 times. The dropper had a line clearly indicating
0.6 ml, and this procedure was reviewed with the patient at the
time of randomization. Patients were instructed to gently shake
the PEG-S solution until the simethicone was dispersed and
the solution clear. Prior investigation demonstrated that
complete dissolution occurs rapidly and PEG-S remains clear
even when refrigerated for more than 12 h (unpublished).
Diet instructions were identical for both the study groups.
The day before colonoscopy, patients were permitted a lowresidue breakfast up to 10:00 AM, followed by clear liquids up
to 2.5 h before the colonoscopy except for medications, which
were permitted with sips of water. Patients received specific
instructions regarding a low-residue diet, including a list
of acceptable and unacceptable foods (Supplementary
Appendix A).
An investigator not performing the colonoscopy contacted
patients within 1 week of their scheduled procedure to review
the instructions. All study procedures were performed by an
attending physician and fellows did not participate. All patients
got monitored anesthesia care administered by a certified
registered nurse anesthetist.
Clinical and Translational Gastroenterology

Assessments. At the time of randomization, demographic
data were collected, including age, gender, indication for
procedure, past medical history, medications, and history of
prior colonoscopy.
On the day of colonoscopy, before the procedure, a safety
assessment was performed including vital signs and orthostatic assessment. Also before colonoscopy, patients completed questionnaires evaluating compliance, side effects,
sleep, satisfaction, and willingness to repeat the purgative.
Side effects were measured using a 10-point Likert scale from
0 (none) to 10 (severe). Sleep quantity was measured by
comparing the average number of hours the patient normally
sleeps to the number of hours they slept the night before
colonoscopy. Sleep quality was rated on a 5-point scale: very
poor, poor, average, good, and very good.
During colonoscopy, the following were recorded: total
procedure and withdrawal time (excluding interventions),
cecal intubation, findings, and specific information regarding
polyps including the number, location, size, morphology,
and method of excision. The endoscopist graded the
presence and severity of bubbles in segments during the
procedure. By convention this was performed on withdrawal
of the colonoscope and recorded after leaving each segment
of colon. The Bubble Scale used for this study graded 4
segments of the colon—cecum, right colon and hepatic
flexure, transverse colon and splenic flexure, and colon
distal to the splenic flexure. Each colon segment was graded
using a 3-point scale where A ¼ no/minimal bubbles, B ¼
moderate bubbles/interfere with detecting a 5 mm polyp,
and C ¼ severe bubbles/interfere with detecting a 10 mm
polyp. Before the start of the study, both participating
endoscopists attended a bubble scale training session during
which multiple images demonstrating examples of grades A,
B, and C were reviewed.
The endoscopist also graded the quality of preparation for
the whole colon and the right colon (excellent, good, fair, or
poor; excellent or good considered ‘‘adequate’’ cleansing). A
descriptor of each preparation grade was available for the
endoscopist to review at the time of assigning the grade
(Supplementary Appendix B). The endoscopist also estimated the amount of flushing required (none, o50, 50–100,
or 4100 cc), and this was performed without simethicone
except where specifically required to clear bubbles not
responsive to standard flushing. When simethicone was
used, it was immediately following withdrawal from a segment
with Grade B or C bubbles, which could not be cleared with
water flush.
When final pathology was available, an investigator not
involved in performing the colonoscopy recorded the histology
results (hyperplastic, adenomatous, cancer, other). For
adenomas, the presence of high-grade dysplasia and villous
component was recorded.
Masking. To ensure blinding, randomization assignments
were concealed in a sealed envelope. After consent, the
investigator would open the envelope to learn the patient
assignment. In order to maintain blinding, patients were
instructed by an investigator not to discuss their preparation
assignment with the endoscopist. In addition, all preparation
instructions were given in a closed exam room without the
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Assessed for eligibility (n= 152)

Enrollment

Excluded (n= 12)
Declined to participate

Randomized (n= 139)

Allocation
PEG (n=69)

PEG-S (n=70)

EXCLUSIONS (n=8)

EXCLUSIONS (n=8)
Withdrew before colonoscopy (n= 6)

Withdrew before colonoscopy (n= 7)
- Cancelled procedure and did not
reschedule (3)
- Declined further participation (4)

- Cancelled procedure and did not
reschedule (3)
- Declined participation (2)
- Rescheduled procedure after study
timeframe (1)
Research coordinator unavailable to collect
pt data during procedure (2)

- Rescheduled procedure after study time
frame (1)
Research coordinator unavailable to collect
pt data during procedure (1)

Colonoscopy terminated
because of poor prep (2)
Analysis
Analyzed (n= 61)
Bubbles (n= 60)
Cleansing (n= 61)
Tolerance (n= 61)
Findings (n= 61)

Analyzed (n= 62)
Bubbles (n= 60)
Cleansing (n= 62)
Tolerance (n= 62)
Findings (n= 60)

Figure 1 (a) With Polyethylene Glycol-Electrolyte Solution (PEG-ELS), 38% of patients had grade B or C bubbles in at least 1 colon segment compared with 2% with PEGELS þ simethicone (PEG-S). (b) Preparation adequacy was similar with PEG-ELS and PEG-S. (c) Significantly less flushing was required with PEG-S. (d) Mean total
procedure time and withdrawal time was not significantly different between the study groups.

endoscopist present. At the time of colonoscopy, the
endoscopists documented whether they had remained blind
to the patients’ preparation through completion of the
colonoscopy and grading of the prep.
Outcome measures. The primary trial end point was the
presence of grade B or C bubbles in any colon segment for
each patient. Secondary end points were quality of cleansing, need for flushing, total procedure and withdrawal time,
incidence and severity of side effects, and polyp detection.
Polyp assessment was done per patient and in total for both
groups, and included the number of all polyps, adenomas,
and high-risk adenomas defined as size 41 cm, high-grade
dysplasia, or villous component.
Statistical analyses. The trial was designed and analyzed
as a superiority trial on all end points (PEG-S better than
PEG-ELS). Under the assumption that the incidence of
bubbles would be about 10% in the simethicone group and
33% in the control group, a sample size of 60 patients per
group yields 88% power (using a two-sided alpha of 0.05).
All patients were analyzed according to the group they were
assigned to, but patients who canceled the procedure or
withdrew from the study before undergoing colonoscopy were
excluded. For dichotomous end points, the difference in
proportions between the simethicone and control groups was
estimated, along with a 95% exact confidence interval.
Testing for dichotomous end points was based on the exact
version of Barnard’s test and for ordered categorical end

points on an exact permutation test. For continuous end
points, the mean or median difference was estimated, along
with a 95% confidence interval. The analyses were conducted
in SAS 9.2 (SAS Institute, Cary, NC) and StatXact 9 (Cytel,
Cambridge, MA).
RESULTS
Participant flow and follow-up. From December 2009 to
July 2010, 152 patients referred for outpatient colonoscopy
were offered entry and 12 declined to participate (Figure 1).
One hundred and thirty nine patients were randomized, and
13 patients withdrew before taking any preparation. Two
patients in the PEG-ELS group and one patient in the PEG-S
were excluded because of inability to collect key data
(Figure 1). The final analyses included 123 patients, of
whom 62 received PEG-S and 61 received PEG-ELS. The
majority (113) of the 123 procedures were performed by the
study’s principal investigator, D.K. Endoscopist masking was
maintained for all cases. Cecal intubation was accomplished
for all but three cases in the PEG-S group (two because of
poor preparation, and one because of stricture) and two in
the PEG-ELS group (one because of technical difficulty and
one patient did not have a cecum but did have intubation of
an ileocolonic anastomosis). Compared with the PEG-ELS
group, the PEG-S group had a higher fraction of women and
a longer interval between preparation and procedure. Table 1
summarizes the characteristics of the study groups and
colonoscopy-related variables.
Clinical and Translational Gastroenterology
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Table 1 Patient and clinical characteristics

PEGELS þ (N ¼ 61)

PEGS þ þ (N ¼ 62)

Age (years), n (%)
r50
51–60
61 þ

18 (30)
22 (36)
21 (34)

17 (27)
26 (42)
19 (31)

Sex, n (%)
Male
Female
Any medical conditions, n (%)

32 (52)
29 (48)
41 (67)

24 (39)
38 (61)
42 (68)

Number of medical conditions,
mean±s.d.a
Hypertension, n (%)
Hyperlipidemia, n (%)
Diabetes, n (%)
Any prior surgery, n (%)
Any medications, n (%)

1.7±1.5

1.5±1.5

25 (41)
22 (36)
8 (13)
20 (33)
52 (82)

20 (32)
14 (23)
8 (13)
18 (29)
53 (85)

Number of medications, mean±s.d.b
Antihypertensive medications,
n (%)
Cardiac medications, n (%)
Acid suppression medications,
n (%)
Aspirin, NSAIDs, or acetaminophen, n (%)
Vitamins, herbs, or supplements,
n (%)

2.3±1.6
22 (36)

2.0±1.5
18 (29)

21 (34)
14 (23)

11 (18)
17 (27)

19 (31)

12 (19)

24 (39)

28 (45)

Indication for colonoscopy, n (%)
Screen/surveillance
Symptoms
First colonoscopy, n (%)

44 (72)
17 (28)
20 (33)

41 (66)
21 (34)
25 (40)

Interval between last prep and
colonoscopy, n (%)
o4 h
44 h

27 (44)
34 (56)

18 (29)
44 (71)

Starting time of colonoscopy,c n (%)
Before 10:00 hours
10:00 hours to noon
Noon to 14:00 hours
After 14:00 hours

10 (17)
22 (37)
12 (20)
16 (27)

12 (20)
19 (32)
21 (35)
8 (13)

NSAID, non-steroidal antiinflammatory drug; ( þ ) PEG-ELS, polyethylene
glycol-electrolyte solution (control); ( þ þ ) PEG-S, polyethylene glycol-electrolyte solution plus simethicone.
Percentages may not sum to 100 because of rounding.
a
Most common conditions listed.
b
Most frequent medications listed.
c
Data unavailable for one PEG-ELS and two PEG-S patients.

Preparation quality. Preparation quality was measured for
the 123 patients who underwent colonoscopy and is summarized in Table 2. A total of 24 patients had grade B or C bubbles
in at least one of the four colon segments assessed, and all but
one of these patients received PEG-ELS (incidence ¼ 2%
PEG-S vs. 38% PEG-ELS, P ¼ 0.001) (Figure 1a).
Controlling for time elapsed between preparation and
procedure, the differences in bubble incidence remained
statistically significant. For time o4 h, incidence was 0%
(0/18) in PEG-S vs. 52% (14/27) in PEG-ELS (P ¼ 0.001),
whereas for time 44 h, incidence was 2% (1/42) and 27%
(9/33), respectively (P ¼ 0.002). A total of eight patients in the
PEG-ELS group and none in the PEG-S group had the most
severe, grade C, bubbles. Thirty-nine of the 236 colon segments
in the PEG-ELS patients, and one of the 238 colon segments in
the PEG-S patients, showed grade B or C bubbles.
Clinical and Translational Gastroenterology

Prep efficacy results are summarized in Table 2. The two
groups were not significantly different in the adequacy of
cleansing for the entire colon (PEG-ELS ¼ 89%, PEG-S 94%;
P ¼ 0.529) and the right colon (PEG-ELS ¼ 88%, PEGS ¼ 94%; P ¼ 0.365) (Figure 1b). Significantly more patients
in the PEG-S group had ‘‘excellent’’ rather than ‘‘good’’
cleansing of both the entire colon (PEG-S ¼ 53%, PEGELS ¼ 28%; P ¼ 0.004) and the right colon (PEG-S ¼ 53%,
PEG-ELS ¼ 35%; P ¼ 0.044). Furthermore, the need for any
flushing was significantly less in the PEG-S group (P ¼ 0.001)
(Figure 1c). No statistically significant differences were found
in withdrawal time (mean ¼ 7.0 min in PEG-S vs. 7.3 min in
PEG-ELS, P ¼ 0.462) or total procedure time (mean ¼ 12.6
min in PEG-S vs. 13.4 min in PEG-ELS, P ¼ 0.277)
(Figure 1d).
Purgative completion, tolerance, and side effects.
Table 3 summarizes the results for measures of purgative
tolerance. Preparation completion was virtually identical
across the two groups. There were no statistically significant
differences in the incidence of side effects or in the severity
of those reported side effects (results not shown). Severe
symptoms rated 7 or higher on the 10-point scale were
reported by seven patients in the PEG-S group vs. eight in
the PEG-ELS group. Measures of duration and quality of
sleep, and overall satisfaction, were also not significantly
different across the two groups. A high percentage of
patients in both groups indicated a willingness to repeat the
assigned purgative in the future.
Colonoscopy findings. Table 4 summarizes the results of
the colonoscopy findings. The proportion of patients in whom
polyps were detected was not significantly different between
the two groups (38% PEG-S vs. 48% PEG-ELS, P ¼ 0.319),
nor was there a significant difference in adenoma detection
(25% PEG-S vs. 33% PEG-ELS, P ¼ 0.380). The number of
polyps per patient and the number of adenomas per patient
were also not significantly different across the two groups.
DISCUSSION
Adequate bowel preparation directly impacts several measures of colonoscopy quality including cecal intubation,
physician adherence to published surveillance guidelines,
and adenoma detection.4,6,15–17 To date, colonic bubbles
have not been formally considered in scales measuring colon
cleansing. However, colonic bubbles are frequently encountered by endoscopists who often address this problem by
adding simethicone to their flushes.
We believe the impact of bubbles on prep adequacy may be
underestimated. In a prior prospective study looking at split
dose PEG-ELS, we detected bubbles having the potential to
interfere with polyp detection in 35% of patients. Colonic
bubbles may be a ubiquitous finding with a variety of
purgatives. The presented findings are similar to the 32%
incidence of bubbles with 5 l PEG-ELS administered on the
day of colonoscopy, and 30% incidence with split dose sodium
phosphate liquid.13,18 In both the studies, the addition of
simethicone significantly reduced the incidence of bubbles.
Our study examined the effect of simethicone on the incidence
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Table 2 Preparation efficacy end points

PEG-ELS (N ¼ 61)

a

Grade B or C bubbles
Cecumb
Right and hepatic flexureb
Transverse and splenic flexurea
Distal to splenic flexurea
Number of colon segments w/Grade B or C bubblesa
0
1
2
3
4
Adequate cleansing, whole colon
Adequate cleansing, right colonc
Flushinga
None
o50 ml
50–100 ml
4100 ml

PEG-S (N ¼ 62)

PEG-S—PEG-ELS

n

%

n

%

D

95% CI

P

23
8
14
13
4

38
14
24
22
7

1
0
0
1
0

2

 36.7
 13.8
 24.1
 20.0
 6.7

 50.2,  24.2
 25.1,  6.5
 37.1,  14.7
 32.7,  9.6
 16.7,  0.3

0.001
0.003
0.001
0.001
0.045
0.001

37
13
5
4
1
54
53

62
22
8
7
2
89
88

59
1
0
0
0
58
58

98
2

94
94

 6.1, 16.7
 6.0, 17.0

0.529
0.365
0.001

23
9
8
20

38
15
13
33

42
11
3
4

70
18
5
7

2

5.0
5.2

D, difference (%) between PEG-S (simethicone) and PEG-ELS (control) groups; CI, confidence interval.
a
N ¼ 60 in each group; data unavailable for a control patient for whom data were not collected and 2 simethicone patients because of aborted procedure (poor prep).
b
N ¼ 58 in control and 59 in simethicone group; data unavailable for the 5 patients with no cecal intubation (see text) plus an additional control patient for whom data
were not collected.
c
N ¼ 60 in control and 62 in simethicone group; data unavailable for 1 control patient whose right colon was not intubated (tortuous colon).

of bubbles having the potential to interfere with polyp
detection. All patients received low volume (2 l) PEG-ELS
with sodium ascorbate and ascorbic acid (MoviPrep) administered as a PM/AM split dose, with 400 mg of liquid simethicone
added to each dose of purgative in the PEG-S group. Similar
to past studies, we found a high incidence of bubbles in those
receiving PEG-ELS, and a marked and significant reduction in
bubbles with the addition of liquid simethicone to the
purgative. Along with this, the group receiving simethicone
had significantly more excellent preps and required significantly less flushing.
Although this study was not powered for the secondary
outcomes assessed, the remainder of comparisons between the
two study groups did not demonstrate significant differences.
Specifically, there were no significant differences between the
two groups with respect to total procedure and withdrawal time,
gastrointestinal adverse events, and polyp detection.
With respect to bubble and polyp detection, as per the study
protocol, patients with bubbles that could not be cleared
without adjuvant use of simethicone added to the water flush
were analyzed per protocol assignment. We observed that
vigorous flushing with water alone often exacerbated the
severity of bubbles. Two patients in the PEG-ELS group
required a simethicone flush. One of these had both distal
segments rated as ‘‘A’’ (no/minimal bubbles) and a single
adenoma was detected in one of these segments. The second
patient had both distal segments rated as ‘‘B’’ (moderate
bubbles/interfere with detecting 5 mm polyp) and no adenoma
detected. To properly power this study to demonstrate a 25%
improvement in adenoma detection with PEG-S would have
required a study with an NB1750.
Luminal bubbles are not a problem unique to colonoscopy,
and have been described as a limiting factor for capsule
endoscopy. Here, the consequences are even greater as

there is no possibility of flushing with simethicone. The use of
simethicone before capsule endoscopy, often with PEG-ELS,
has become an accepted practice and its small bowel
cleansing superiority has been demonstrated in a metaanalysis.19 Bubbles are one of the five criteria in a validated
scoring system for small bowel cleansing for capsule
endoscopy.20 Whether bubbles form spontaneously in the
colon is unknown, but on numerous occasions we have
witnessed copious bubbles flowing through the ileocecal valve
into the cecum during routine colonoscopy. That the small
bowel is a primary source of bubbles is suggested by our
observation that the lowest frequency of colonic bubbles
occurs distal to the splenic flexure.14
Simethicone has been available over-the-counter for over
50 years, and its use in infants, children, and adults is
considered quite safe. As an adjunct to colon purgation, past
studies have evaluated the addition of simethicone to both
aqueous sodium phosphate liquid and 4 l PEG-ELS. Similar to
our study, these studies consistently found a high incidence of
bubbles with the control purgative, and a striking diminution of
bubbles with the addition of simethicone. Although there has
been speculation that bubbles are more of an issue with PEG,
these referenced studies suggest bubbles occur at least as
often with sodium phosphate.
Simethicone’s effect on prep efficacy has yielded
mixed results. Shaver et al.13 showed significantly better
colon cleansing with simethicone and alluded to improvement
in the right colon, a region more likely to be affected
by adherent dense chyme. Tongprasert et al.1 showed that
simethicone added to sodium phosphate improved visibility by
diminishing bubbles. In the same study, there was a
trend toward better colon cleansing with the addition of
simethicone to sodium phosphate, though it did not reach
statistical significance. McNally et al.21 evaluated the
Clinical and Translational Gastroenterology
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Table 3 Preparation tolerance

PEG-ELS (N ¼ 61)

PEG-S (N ¼ 62)

PEG-S – PEG-ELS

n

%

n

%

D

95% CI

P

490% prep completion
490% pm prep completion
490% am prep completion
Any side effects
Nausea
Vomiting
Abdominal pain
Bloating
Light headedness

55
57
56
40
18
3
21
32
15

90
93
92
66
30
5
34
53
25

56
58
56
39
22
3
17
25
17

90
94
90
63
36
5
27
40
27

0.2
0.1
 1.5
 2.7
6.0
0.0
 7.0
 12.1
2.8

 11.3, 11.6
 10.1, 10.3
 12.7, 10.1
 19.6, 14.4
 11.3, 22.5
 10.1, 9.8
 23.8, 10.0
 30.0, 5.8
 12.9, 18.8

1.000
1.000
1.000
0.783
0.501
1.000
0.422
0.207
0.799

Any severe side effects (7 þ score)
Severe nausea
Severe vomiting
Severe abdominal pain
Severe bloating
Severe light headedness
Slept o50% of usual time

8
4
1
0
5
0
13

13
7
2

11
7
3
2
5
2
16

 1.8

 14.3, 10.6

0.829

21

7
4
2
1
3
1
10

 5.2

 19.5, 9.8

0.522

Awake at night
Number of times upa
Number of times to the bathrooma

43

70

41

66

 4.4

 20.8, 12.7

0.633
0.704
0.557

8

Median ¼ 2
Median ¼ 2

Median ¼ 2
Median ¼ 2

Quality of sleep
Very poor
Poor
Average
Good
Very good

6
10
17
18
10

10
16
28
30
16

3
13
26
13
7

5
21
42
21
11

0.522

Satisfaction
10 (High)
9
8
7
6
5
4
3
2
0 (low)
Would use prep again

21
0
11
1
13
1
4
2
4
4
46

34
18
2
21
2
7
3
7
7

20
1
15
1
10
3
4
0
4
4
50

32
2
24
2
16
5
6
6
6

0.769

75

81

5.2

 10.0, 20.5

0.515

D, difference (%) between PEG-S (simethicone) and PEG-ELS (control) groups; CI, confidence interval.
a
Only among those who awoke during the night.

Table 4 Colonoscopy findings

Patients with polyp(s) detected a
Number of polyps per patienta
0
1
2
3þ
Patients with adenoma(s) detected a
Number of adenomas
per patient a
0
1
2
3þ
Patients with high-risk adenoma detected a

PEG-ELS (N ¼ 61)

PEG-S (N ¼ 62)

n

%

n

%

D

95% CI

P

29

48

23

38

 9.2

 26.6, 9.1

0.319
0.562

32
12
10
7
20

52
20
16
12
33

37
8
5
10
15

62
13
8
17
25

 7.8

 23.8, 9.1

0.380
1.000

41
8
6
6
2

67
13
10
10
3

45
6
3
6
0

75
10
5
10
 3.3

 11.5, 2.9

0.209

PEG-S – PEG-ELS

D, difference (%) between PEG-S (simethicone) and PEG-ELS (control) groups; CI, confidence interval; High-risk adenoma, adenoma 41 cm or with high grade
dysplasia or with villous component.
a
N ¼ 61 in control and 60 in simethicone group; data unavailable for 2 simethicone patients because of aborted procedure (poor prep).

Clinical and Translational Gastroenterology

The Effects of PEG-ELS and Simethicone on Colonic Bubbles
Matro et al.

7

effectiveness of simethicone in improving visibility by rating
degree of bubbles as well as haziness. Haziness was
defined as blurriness of vision independent of preparation
adequacy and was rated according to the amount of water
required to clear the endoscope lens. Patients with simethicone added to the colon purgative had significantly lower
haziness scores and mean bubble scores compared with
patients who did not receive simethicone, resulting in
improved colonic visibility.
As gastrointestinal adverse events are a common
problem with all purgatives, interventions to lessen this would
be welcomed. Lazzaroni et al.22 described significantly
reduced malaise and sleep disturbance, and a trend toward
improved tolerance, when simethicone was used in conjunction with PEG-ELS. Tongprasert et al.1 found superior patient
satisfaction with simethicone, though specific gastrointestinal
adverse events were not different between study groups.
Endoscopists in the simethicone arm were also more
satisfied, likely due to better visualization and less need to
flush. Our study did not find fewer adverse events in the
simethicone group.
There are several weaknesses to our study. This study was
greatly underpowered (more than 10-fold) to detect potentially
important secondary outcomes such as actual differences in
adenoma detection or side effects. Second, patients in the
control arm did not receive a simethicone placebo, which may
have impacted measures obtained by patient self-assessment (GI adverse events, prep completion, sleep, satisfaction,
and willingness to repeat the preparation). For none of these
measures did we detect a statistical difference between the
study groups, but further studies should utilize a simethicone
placebo. Furthermore, the majority of colonoscopies were
done by one physician who developed the grading scale.
Though an education session was performed before starting
the study to ensure consistent (intra-observer) grading, too
few cases were done by the other endoscopist to assess
differences between the two. Although the readers were
blinded to the assigned purgative, overestimation of the
impact of bubbles on polyp detection could have resulted in a
high proportion of patients deemed to have significant (grade
B or C) bubbles. It is somewhat reassuring that the 38%
incidence of bubbles in this study’s control group is similar to
four past published studies (30%—Sudduth, 33%—Rubin,
32%—Shaver, 42% Tongprasert), though this is the first to
specifically include bubbles that could potentially impact the
detection of polyps Z5 mm.1,13,14,18
In summary, the addition of simethicone to each 1 l dose of
split PEG-ELS resulted in a marked and significant reduction
of luminal bubbles that could interfere with polyp detection.
Larger studies will be needed to assess whether the addition
of simethicone results in additional benefits such as reduced
adverse events, greater endoscopist efficiency, and actual
superior polyp detection.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| Colonic bubbles are commonly encountered during
colonoscopy with both hyperosmotic and isosmotic
purgatives.
| The clinical relevance of colonic bubbles is suggested by
the common practice of adding simethicone to water
flushes during colonoscopy.

WHAT IS NEW HERE
| Using the current ‘‘best practice’’ of split dosing, the
addition of simethicone to low volume PEG-ELS effectively
eliminates colonic bubbles.
| The addition of simethicone to PEG-ELS also reduces the
need for any intra-procedure flushing and improves the
proportion of patients with excellent colon cleansing.
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